We are live on ! Find out more
EIDX

Eidos Therapeutics, Inc. Common Stock
EIDX

Delisted

EIDX was delisted on the 25th of January, 2021.

Back to rankings

0 hedge funds and large institutions have $0 invested in Eidos Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 120 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 121 → 0 (-121)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $1.45B → $0 (-$1.45B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 120

Holders
–
Holders Change
-121
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
120
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$205M
2
ACM
Aisling Capital Management
New York
-$148M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$119M
4
PA
Perceptive Advisors
New York
-$90.4M
5
MF
Magnetar Financial
Illinois
-$78.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
AQR Capital Management
76
AQR Capital Management
Connecticut
– -$954K -7,249 Closed
PPA
77
Parametric Portfolio Associates
Washington
– -$939K -7,140 Closed
Manulife (Manufacturers Life Insurance)
78
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$939K -7,136 Closed
BHMP
79
Bardin Hill Management Partners
New York
– -$900K -6,837 Closed
Victory Capital Management
80
Victory Capital Management
Texas
– -$754K -5,732 Closed
JP Morgan Chase
81
JP Morgan Chase
New York
– -$671K -5,096 Closed
VOYA Investment Management
82
VOYA Investment Management
Georgia
– -$617K -4,687 Closed
Susquehanna International Group
83
Susquehanna International Group
Pennsylvania
– -$600K -4,560 Closed
MAM
84
Martingale Asset Management
Massachusetts
– -$593K -4,503 Closed
Millennium Management
85
Millennium Management
New York
– -$584K -4,435 Closed
State Board of Administration of Florida Retirement System
86
State Board of Administration of Florida Retirement System
Florida
– -$583K -4,434 Closed
MIM
87
MetLife Investment Management
New Jersey
– -$574K -4,364 Closed
MLICM
88
Metropolitan Life Insurance Company (MetLife)
New York
– -$397K -3,018 Closed
Handelsbanken Fonder
89
Handelsbanken Fonder
Sweden
– -$395K -3,000 Closed
ASRS
90
Arizona State Retirement System
Arizona
– -$368K -2,797 Closed
Principal Financial Group
91
Principal Financial Group
Iowa
– -$365K -2,771 Closed
VEA
92
Virtus ETF Advisers
New York
– -$342K -2,601 Closed
Two Sigma Advisers
93
Two Sigma Advisers
New York
– -$342K -2,600 Closed
Marshall Wace
94
Marshall Wace
United Kingdom
– -$316K -2,403 Closed
Invesco
95
Invesco
Georgia
– -$310K -2,358 Closed
Bank of Montreal
96
Bank of Montreal
Ontario, Canada
– -$271K -2,145 Closed
BNP Paribas Financial Markets
97
BNP Paribas Financial Markets
France
– -$271K -2,062 Closed
GI
98
GAMCO Investors
Connecticut
– -$263K -2,000 Closed
AB
99
Amalgamated Bank
New York
– -$225K -1,708 Closed
Legal & General Group
100
Legal & General Group
United Kingdom
– -$207K -1,573 Closed
1 2 3
4
5

EIDX Hedge Fund Activity: Q1 2021 in Review

0 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q1 2021, worth a combined $0 — down 100% from $1.45B a quarter earlier.

Sellers outnumbered buyers: 120 funds closed out of EIDX and 0 opened new positions — a net loss of 120 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $205M sold.

  • 0 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q1 2021, down from 121 in Q4 2020.
  • Funds reported $0 of Eidos Therapeutics, Inc. Common Stock stock for Q1 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q1 2021 and 120 closed out, a net change of -120 holders.
  • The largest Eidos Therapeutics, Inc. Common Stock seller in Q1 2021 was BlackRock, an estimated $205M sold.

Based on aggregated 13F filings for Q1 2021.